Medical Pharmacology: Chapter 34 — Anti-Cancer Drugs Part II -- Module 4 — Immune Checkpoint Inhibitors, Hormonal Oncology, and CAR-T Cell Therapy: Conceptual Understanding

Chapter 34 — Anti-Cancer Drugs Part II — Module 4 — Immune Checkpoint Inhibitors, Hormonal Oncology, and CAR-T Cell Therapy: Conceptual Understanding

1. A patient with advanced melanoma is started on combination ipilimumab (a CTLA-4 inhibitor, acting during T-cell priming) plus nivolumab (a PD-1 inhibitor, acting at the tumor in the effector phase). Integrating the phase-of-action of each agent with their toxicity profiles, what should the clinician anticipate compared with single-agent PD-1 blockade?

A) Fewer immune-related adverse events overall, because the two agents neutralize each other's immune activation.
B) A higher rate and earlier onset of immune-related adverse events, because releasing the brake at both the priming and effector phases produces broader T-cell activation, so the team should be prepared for prompt corticosteroid initiation.
C) Toxicity limited strictly to the skin, because dual blockade only affects dermal T cells.
D) No change in toxicity, because adding a second checkpoint inhibitor does not alter immune activation.
E) Predictable myelosuppression at days 10 to 14, identical to cytotoxic chemotherapy.

ANSWER: B

Rationale:

Blocking CTLA-4 broadens the pool of primed T cells in lymph nodes and blocking PD-1 restores effector activity at the tumor; combining the two amplifies T-cell activation at both phases. Because immune-related adverse events arise from that same activation, the combination produces more frequent and often earlier and more severe events, so clinicians must be ready to start corticosteroids promptly.

Option A: Option A is incorrect because the agents act at complementary phases and do not neutralize each other; toxicity rises rather than falls.
Option C: Option C is incorrect because dual blockade causes multi-organ autoimmune toxicity (colitis, hepatitis, pneumonitis, endocrinopathies), not skin-limited effects.
Option D: Option D is incorrect because adding CTLA-4 blockade demonstrably increases immune activation and toxicity.
Option E: Option E is incorrect because checkpoint inhibitors cause immune-mediated, not predictable cytotoxic, myelosuppression.

2. A patient on combination checkpoint inhibitor therapy develops both steroid-refractory immune colitis and, simultaneously, rising transaminases consistent with immune hepatitis. High-dose corticosteroids have not controlled either process. Integrating the organ-specific steroid-sparing strategies for these two immune-related adverse events, what is the most appropriate next step?

A) Add infliximab to cover both the colitis and the hepatitis, since it is the universal steroid-sparing agent.
B) Withhold all further immunosuppression and resume both checkpoint inhibitors.
C) Add mycophenolate mofetil for both processes and rechallenge with the CTLA-4 agent in one week.
D) Add mycophenolate mofetil to address the hepatitis (infliximab is avoided in hepatitis because of its own hepatotoxicity), recognizing that mycophenolate also provides immunosuppression for the refractory colitis in this combined presentation.
E) Give a somatostatin analog to control both the diarrhea and the hepatic inflammation.

ANSWER: D

Rationale:

The two events require different steroid-sparing logic: infliximab is the agent of choice for refractory colitis but is avoided in immune hepatitis because anti-TNF therapy is itself hepatotoxic. When hepatitis is present, mycophenolate mofetil is the correct steroid-sparing choice for the liver, and it provides systemic immunosuppression that also addresses the refractory colitis, avoiding the hepatotoxic infliximab.

Option A: Option A is incorrect because infliximab is contraindicated by the concurrent hepatitis.
Option B: Option B is incorrect because refractory dual organ toxicity requires escalation of immunosuppression, not withdrawal, and rechallenge is inappropriate.
Option C: Option C is incorrect because rechallenging the CTLA-4 agent after severe refractory toxicity is contraindicated.
Option E: Option E is incorrect because somatostatin analogs treat neuroendocrine tumors and have no role in immune colitis or hepatitis.

3. A patient on a checkpoint inhibitor is found to have both new central hypothyroidism and laboratory evidence of secondary adrenal insufficiency from immune-mediated hypophysitis (pituitary inflammation). The clinician plans hormone replacement. Integrating the physiology of these two endocrine deficits, what is the correct sequence and why?

A) Replace glucocorticoid (hydrocortisone) first and then begin levothyroxine, because starting thyroid hormone before cortisol replacement can accelerate cortisol metabolism and precipitate an adrenal crisis.
B) Start levothyroxine first and add hydrocortisone only if symptoms persist, because thyroid replacement is always the higher priority.
C) Replace neither hormone and instead increase the checkpoint inhibitor dose to restore pituitary output.
D) Give fludrocortisone alone, since mineralocorticoid replacement corrects both deficits.
E) Begin both hormones only after a 2-week observation period without any treatment.

ANSWER: A

Rationale:

When central hypothyroidism and adrenal insufficiency coexist, glucocorticoid replacement must come first: levothyroxine increases metabolic rate and hepatic cortisol clearance, so giving it before cortisol replacement can unmask or precipitate adrenal crisis. Hydrocortisone is started first, then levothyroxine is added.

Option B: Option B inverts the safe sequence and risks adrenal crisis.
Option C: Option C is incorrect because raising the checkpoint inhibitor dose cannot restore pituitary function and may worsen gland injury.
Option D: Option D is incorrect because central (secondary) adrenal insufficiency requires glucocorticoid replacement; mineralocorticoid alone is inadequate and does not treat hypothyroidism.
Option E: Option E is incorrect because both deficits require timely replacement, and delay risks adrenal crisis.

4. A patient has a metastatic solid tumor of a type for which checkpoint inhibitors are not routinely first-line, but molecular testing reports the tumor as microsatellite instability-high/mismatch-repair-deficient (MSI-H/dMMR — a defect in the DNA mismatch-repair system). Integrating the mechanism behind this biomarker with the basis of checkpoint inhibitor response, what is the best prediction?

A) The tumor is unlikely to respond, because MSI-H/dMMR status reduces the number of tumor neoantigens.
B) Response cannot be predicted by molecular testing and depends solely on the anatomic tumor site.
C) The tumor is relatively likely to respond to PD-1 blockade, because mismatch-repair deficiency generates a high mutational and neoantigen load that makes the tumor more visible to T cells, and this predicts response across tumor types.
D) MSI-H/dMMR status predicts response only when PD-L1 expression is simultaneously absent.
E) The biomarker predicts response only to hormonal therapy, not to checkpoint blockade.

ANSWER: C

Rationale:

Mismatch-repair deficiency leaves errors uncorrected, producing a high mutational burden and abundant neoantigens; these make the tumor more recognizable to T cells, which is why MSI-H/dMMR predicts response to PD-1 blockade in a tissue-agnostic manner — across tumor types rather than by anatomic site.

Option A: Option A is incorrect because dMMR increases, not decreases, neoantigen load.
Option B: Option B is incorrect because this is precisely a setting where a molecular biomarker (not anatomic site) predicts benefit.
Option D: Option D is incorrect because MSI-H/dMMR predicts response independently and is not contingent on absent PD-L1.
Option E: Option E is incorrect because the biomarker predicts response to checkpoint blockade, not hormonal therapy.

5. A renal transplant recipient on maintenance immunosuppression develops an advanced cancer for which a PD-1 inhibitor would ordinarily be considered. Integrating how PD-1/PD-L1 blockade works with the biology of a transplanted organ, what is the principal concern, and how should it be framed?

A) There is no special concern, because checkpoint inhibitors act only on tumor cells and spare transplanted organs.
B) The main risk is predictable bone marrow suppression, identical to cytotoxic chemotherapy, and the graft is not at risk.
C) The transplant guarantees that the tumor will respond, so checkpoint blockade can be given without monitoring.
D) The concern is that maintenance immunosuppression will completely prevent any checkpoint inhibitor activity, so the dose should simply be doubled.
E) Releasing the PD-1/PD-L1 brake can reactivate alloreactive T cells against the graft, carrying a high risk of acute allograft rejection (reported around 40% in renal transplant case series), so the decision requires weighing tumor benefit against graft loss.

ANSWER: E

Rationale:

PD-1/PD-L1 signaling helps maintain peripheral tolerance, including tolerance to a transplanted organ. Blocking that axis can reactivate alloreactive T cells and precipitate acute graft rejection — reported at roughly 40% in renal allograft case series — so checkpoint blockade in a transplant recipient demands an explicit risk-benefit discussion balancing tumor control against the possibility of losing the graft.

Option A: Option A is incorrect because checkpoint inhibitors act broadly on T-cell tolerance, not solely on tumor cells.
Option B: Option B is incorrect because the toxicity is immune-mediated graft rejection, not predictable cytotoxic myelosuppression.
Option C: Option C is incorrect because a transplant does not ensure tumor response and intensive monitoring is required.
Option D: Option D is incorrect because the problem is graft-directed immune reactivation, not a need to double the dose; escalating the dose would increase rejection risk.

6. A patient who is about to start a PD-1 inhibitor is taking chronic prednisone 30 mg/day for an unrelated inflammatory condition. Integrating the mechanism of checkpoint blockade with the pharmacology of systemic corticosteroids, how should this baseline steroid use be addressed?

A) The baseline steroid is irrelevant to checkpoint inhibitor efficacy and requires no change before starting therapy.
B) High-dose baseline corticosteroids can attenuate checkpoint inhibitor response by broadly suppressing the very T-cell activity the drug aims to unleash, so tapering to less than about 10 mg/day of prednisone equivalent before initiation is preferred when clinically feasible.
C) The baseline steroid should be increased to maximize checkpoint inhibitor efficacy.
D) The checkpoint inhibitor will completely fail in any patient on steroids, so it should never be offered.
E) Baseline steroids prevent all immune-related adverse events, so the dose should be maintained high throughout therapy as prophylaxis.

ANSWER: B

Rationale:

Checkpoint inhibitors work by restoring T-cell activity, but high-dose systemic corticosteroids broadly suppress T cells and can blunt that response; retrospective data link baseline prednisone above roughly 10 mg/day to attenuated efficacy. Tapering below that threshold before initiation, when clinically feasible, is therefore preferred.

Option A: Option A is incorrect because high-dose baseline steroids do affect efficacy.
Option C: Option C is incorrect because increasing steroids would further suppress the T-cell response.
Option D: Option D is incorrect because steroids attenuate but do not categorically abolish response, and therapy can still be appropriate after tapering.
Option E: Option E is incorrect because maintaining high-dose steroids as prophylaxis would undermine efficacy and is not standard; immune-related adverse events are treated when they occur rather than blanket-prevented with high-dose steroids.

7. A man with metastatic prostate cancer is started on enzalutamide (a strong inducer of CYP3A4 and several other drug-metabolizing enzymes). His medication list includes apixaban (a direct oral anticoagulant), a CYP3A4-metabolized statin, and an oral oncology agent metabolized by CYP3A4. Integrating enzyme-induction pharmacology with this polypharmacy, what is the correct expectation and action?

A) All three co-administered drugs will accumulate to toxic levels, so each dose should be reduced.
B) Only enzalutamide's own metabolism is affected, so the other drugs need no review.
C) Apixaban levels will rise sharply, mandating an immediate increase in its dose to prevent bleeding.
D) Plasma concentrations of the anticoagulant, statin, and oncology agent are all likely to fall because of accelerated CYP3A4-mediated clearance, so the full medication list should be reviewed at initiation and after any dose change, with substitutions or monitoring as needed.
E) Enzalutamide will convert the statin into an active anticoagulant, eliminating the need for apixaban.

ANSWER: D

Rationale:

Strong CYP3A4 induction increases clearance of CYP3A4 substrates, lowering their plasma levels; with enzalutamide, the anticoagulant, statin, and CYP3A4-metabolized oncology agent are all liable to fall in concentration and lose effect. The correct action is to review the entire medication list at initiation and after any dose change, substituting agents or intensifying monitoring as needed.

Option A: Option A is incorrect because induction lowers, rather than raises, substrate levels.
Option B: Option B is incorrect because a strong inducer affects many co-administered substrates, not only enzalutamide itself.
Option C: Option C is incorrect because anticoagulant levels fall (raising thrombosis, not bleeding, risk) rather than rising.
Option E: Option E is incorrect because enzalutamide does not chemically transform a statin into an anticoagulant.

8. A man on abiraterone (a CYP17A1 inhibitor) for prostate cancer presents with blood pressure 158/96 mmHg and a serum potassium of 3.1 mEq/L. Integrating the enzymatic cascade triggered by CYP17A1 inhibition with the required co-therapy, what is the best interpretation and management?

A) This reflects mineralocorticoid excess from CYP17A1 inhibition (cortisol falls, ACTH rises, mineralocorticoid precursors accumulate); confirm the patient is actually taking prednisone 5 mg twice daily, replete potassium, add an antihypertensive as needed, and reinforce that abiraterone is taken on an empty stomach.
B) This indicates abiraterone underdosing; the dose should be increased and the prednisone stopped.
C) The hypertension and hypokalemia are unrelated to abiraterone and require no change in oncology therapy.
D) The findings represent cortisol excess, so the prednisone should be discontinued immediately.
E) This is a sign that abiraterone has been converted to a mineralocorticoid antagonist, so potassium should be restricted.

ANSWER: A

Rationale:

Inhibiting CYP17A1 lowers cortisol, which raises ACTH (adrenocorticotropic hormone) and drives accumulation of mineralocorticoid precursors upstream of the blocked enzyme, producing hypertension and hypokalemia. The correct response integrates this cascade with the mandatory co-therapy: verify prednisone 5 mg twice daily is actually being taken (it suppresses ACTH and replaces cortisol), correct the potassium, add an antihypertensive if needed, and reinforce empty-stomach dosing.

Option B: Option B is incorrect because the syndrome reflects the expected pharmacology, not underdosing, and stopping prednisone would worsen it.
Option C: Option C is incorrect because the derangement is directly caused by abiraterone's mechanism.
Option D: Option D is incorrect because the problem is reduced cortisol with mineralocorticoid excess, not cortisol excess; stopping prednisone would aggravate it.
Option E: Option E is incorrect because abiraterone causes mineralocorticoid excess, not antagonism, and potassium needs repletion rather than restriction.

9. A premenopausal woman on adjuvant tamoxifen is found to carry a CYP2D6 poor-metabolizer genotype and is also taking paroxetine (a strong CYP2D6 inhibitor) prescribed elsewhere for depression. Integrating the concept of tamoxifen's metabolic activation with the combined effect of genotype and an inhibitor drug, what is the expected consequence?

A) Endoxifen levels will be supratherapeutic, causing tamoxifen toxicity that requires a dose reduction.
B) There will be no effect on endoxifen, because genotype and drug inhibition cancel each other out.
C) Endoxifen formation will be markedly reduced because an already-impaired CYP2D6 genotype combined with a strong CYP2D6 inhibitor produces near-absent enzyme activity (phenoconversion to a poor-metabolizer phenotype), predicting diminished tamoxifen benefit; the paroxetine should be switched to a non-inhibiting agent.
D) Tamoxifen will be converted directly to an estrogen agonist, stimulating the tumor.
E) The combination increases CYP2D6 activity, raising endoxifen above normal.

ANSWER: C

Rationale:

Tamoxifen requires CYP2D6 to form active endoxifen. A poor-metabolizer genotype already limits enzyme activity; adding a strong CYP2D6 inhibitor (paroxetine) drives activity toward near-absent — phenoconversion to a functional poor-metabolizer state — so endoxifen formation is markedly reduced and tamoxifen benefit is likely diminished. The corrective action is to replace paroxetine with a non-inhibiting agent (for example, venlafaxine).

Option A: Option A is incorrect because endoxifen is reduced, not supratherapeutic.
Option B: Option B is incorrect because the two effects compound rather than cancel.
Option D: Option D is incorrect because reduced activation does not convert tamoxifen into an estrogen agonist.
Option E: Option E is incorrect because inhibition decreases, not increases, CYP2D6 activity.

10. A postmenopausal woman with ER-positive metastatic breast cancer progresses after an extended course of an aromatase inhibitor. Liquid biopsy (circulating tumor DNA) detects an ESR1 (estrogen receptor 1 gene) mutation. Integrating the mechanism of aromatase inhibitor resistance with the rationale for the next agent, which choice and reasoning are correct?

A) Re-treat with a higher dose of the same aromatase inhibitor, because ESR1 mutations increase sensitivity to aromatase blockade.
B) Switch to tamoxifen monotherapy, because ESR1-mutant receptors lose all estrogen responsiveness.
C) Add a CYP3A4 inducer to lower estrogen levels further.
D) Begin a GnRH agonist, since ovarian suppression overcomes ESR1-mediated resistance in postmenopausal women.
E) Use a selective estrogen receptor degrader such as oral elacestrant, because ESR1 mutations cause ligand-independent receptor activation that aromatase inhibition cannot overcome, and elacestrant is specifically indicated for ESR1-mutant disease after prior endocrine therapy.

ANSWER: E

Rationale:

ESR1 mutations produce a constitutively active, ligand-independent estrogen receptor, so lowering estrogen with an aromatase inhibitor no longer controls signaling — the basis of acquired resistance. A selective estrogen receptor degrader that eliminates the receptor itself is the rational next step, and elacestrant is specifically indicated for ESR1-mutant metastatic disease after endocrine therapy.

Option A: Option A is incorrect because ESR1 mutation confers resistance to, not enhanced sensitivity to, aromatase blockade.
Option B: Option B is incorrect because tamoxifen, a partial agonist, is not the targeted choice for ligand-independent ESR1-mutant receptors.
Option C: Option C is incorrect because the receptor is active independent of estrogen, so further lowering estrogen does not help, and a CYP3A4 inducer is not an endocrine strategy.
Option D: Option D is incorrect because the patient is postmenopausal, so ovarian suppression with a GnRH agonist does not address the ESR1-driven, estrogen-independent signaling.

11. Two CD19-directed CAR-T products differ in their co-stimulatory domain: one uses CD28 and the other uses 4-1BB. Before infusion, both patients receive lymphodepleting chemotherapy with fludarabine and cyclophosphamide. Integrating the role of the co-stimulatory domain with the purpose of lymphodepletion, which statement is correct?

A) Lymphodepletion is given to suppress the CAR-T cells so they expand more slowly, and the co-stimulatory domain has no effect on the timing of cytokine release syndrome.
B) Lymphodepletion creates cytokine space (including IL-7 and IL-15) and removes competing lymphocytes to support CAR-T expansion and persistence, while CD28-based constructs tend to drive faster, earlier expansion and often earlier cytokine release syndrome than 4-1BB-based constructs.
C) Lymphodepletion is unnecessary and is given only to treat the underlying cancer directly, and both constructs behave identically.
D) The 4-1BB domain causes the most rapid onset of cytokine release syndrome, and lymphodepletion exists to prevent CAR-T persistence.
E) Lymphodepletion eliminates the need to monitor for cytokine release syndrome, regardless of construct.

ANSWER: B

Rationale:

Lymphodepleting chemotherapy removes competing endogenous lymphocytes and creates cytokine space (notably IL-7 and IL-15) that supports CAR-T expansion and persistence. The co-stimulatory domain shapes kinetics: CD28-based constructs generally expand faster and are associated with earlier cytokine release syndrome onset than 4-1BB-based constructs.

Option A: Option A is incorrect because lymphodepletion supports, rather than suppresses, CAR-T expansion, and the domain does influence cytokine release syndrome timing.
Option C: Option C is incorrect because lymphodepletion is integral to CAR-T conditioning (not direct anticancer therapy) and the constructs are not identical.
Option D: Option D inverts the kinetics — CD28, not 4-1BB, is associated with earlier onset, and lymphodepletion promotes rather than prevents persistence.
Option E: Option E is incorrect because vigilant monitoring for cytokine release syndrome is always required after CAR-T infusion.

12. On day 6 after CAR-T infusion, a patient simultaneously develops high fever with vasopressor-dependent hypotension (severe cytokine release syndrome) and new confusion with aphasia (ICANS). Integrating the distinct treatments of these two syndromes when they co-occur, what is the correct approach?

A) Treat with tocilizumab only, because it covers both cytokine release syndrome and ICANS equally well.
B) Treat with dexamethasone only and withhold tocilizumab, because steroids alone resolve both syndromes.
C) Withhold all therapy and observe, since the two syndromes neutralize each other when they overlap.
D) Recognize that the two syndromes require different agents (tocilizumab for cytokine release syndrome, corticosteroids for ICANS); treat the more severe condition first and initiate both tocilizumab and dexamethasone, because tocilizumab does not treat ICANS and may worsen it while steroids are needed for the neurotoxicity.
E) Give a GnRH agonist plus an aromatase inhibitor to control the combined inflammatory response.

ANSWER: D

Rationale:

Cytokine release syndrome and ICANS are mechanistically and therapeutically distinct: tocilizumab targets IL-6-driven cytokine release syndrome but is ineffective for ICANS and may worsen it, whereas corticosteroids (dexamethasone) treat the neurotoxicity. When both co-occur, the correct approach is to treat the more severe condition first and initiate both agents — tocilizumab for the cytokine release syndrome and dexamethasone for the ICANS.

Option A: Option A is incorrect because tocilizumab does not adequately treat ICANS and may aggravate it.
Option B: Option B is incorrect because steroids alone do not provide the targeted IL-6 blockade needed for severe cytokine release syndrome.
Option C: Option C is incorrect because both syndromes are dangerous and require prompt treatment, not observation.
Option E: Option E is incorrect because GnRH agonists and aromatase inhibitors are endocrine cancer therapies with no role in cytokine release syndrome or ICANS.

13. A patient with a functional neuroendocrine tumor is being managed with a somatostatin analog to suppress hormone secretion. The team is weighing octreotide or lanreotide against pasireotide, which has broader somatostatin-receptor affinity (including SSTR5). Integrating receptor pharmacology with the metabolic consequences, which statement best guides selection?

A) Pasireotide's broader receptor activity (notably at SSTR5) provides wider secretory suppression but markedly increases hyperglycemia by suppressing insulin secretion, so octreotide or lanreotide is generally preferred for routine secretory control unless the broader profile is specifically needed, with intensified glucose monitoring if pasireotide is used.
B) Pasireotide causes less hyperglycemia than octreotide because broader receptor binding protects insulin secretion.
C) Octreotide and pasireotide are pharmacologically identical, so selection is arbitrary.
D) All somatostatin analogs are contraindicated in neuroendocrine tumors because they accelerate tumor growth.
E) Pasireotide is preferred specifically because it raises insulin secretion and lowers blood glucose.

ANSWER: A

Rationale:

Pasireotide binds a broader range of somatostatin receptors (including SSTR5), giving wider secretory suppression, but its SSTR5 activity strongly suppresses insulin secretion and causes substantially more hyperglycemia than octreotide or lanreotide. Integrating the receptor profile with this metabolic tradeoff, octreotide or lanreotide is generally preferred for routine secretory control, with pasireotide reserved for when its broader profile is needed and accompanied by intensified glucose monitoring.

Option B: Option B is incorrect because pasireotide causes more, not less, hyperglycemia.
Option C: Option C is incorrect because the agents differ in receptor affinity and metabolic effects.
Option D: Option D is incorrect because somatostatin analogs suppress secretion and provide antiproliferative benefit in well-differentiated neuroendocrine tumors rather than accelerating growth.
Option E: Option E is incorrect because pasireotide suppresses insulin and raises glucose rather than lowering it.